DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Wegovy mimics GLP-1, a natural gut hormone. It slows gastric emptying, reduces appetite, and signals fullness — leading to reduced caloric intake.
Wegovy (semaglutide 2.4mg) is a glucagon-like peptide-1 receptor agonist. It mimics GLP-1, a natural gut hormone released after eating. Three mechanisms drive weight loss: (1) Slows gastric emptying — food stays in your stomach longer, prolonging fullness; (2) Acts on appetite-regulation centers in the hypothalamus — reduces hunger signals and "food noise" (intrusive thoughts about food); (3) Improves insulin sensitivity and glucagon regulation. Net effect: patients consume ~20-30% fewer calories without consciously restricting. Weight loss plateaus at ~12-18 months as the body adapts. Without continued use, ~60% of lost weight returns within 12 months. The cardiovascular outcomes from SELECT trial suggest benefits beyond weight loss, particularly in patients with established CVD.
Editorial answer reviewed by a board-certified clinician. Not medical advice. Coordinate treatment decisions with your prescriber.